Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.

Si, Tianmei; Zhuo, Jianmin; Turkoz, Ibrahim; Mathews, Maju; Tan, Wilson L.W.; Feng, Yu.

doi:10.1080/14656566.2017.1401608

Record: found
Abstract: found
Article: not found

Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.

Author(s): Tianmei Si ¹ , Jianmin Zhuo ² , Ibrahim Turkoz ³ , Maju Mathews ³ , Wilson Tan ⁴ , Yu Feng ⁴

Publication date (Electronic): Dec 2017

Journal: Expert opinion on pharmacotherapy

Publisher: Informa UK Limited

Keywords: Chronic schizophrenia, clinical global impressions – severity (CGI-S), long-acting injectable, paliperidone palmitate, positive and negative syndrome scale (PANSS), recently diagnosed schizophrenia

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The use of long-acting injectable antipsychotics in recently diagnosed schizophrenia remains less explored. We evaluated the efficacy and safety of paliperidone palmitate once-monthly (PP1M) treatment in adult patients with recently diagnosed vs. chronic schizophrenia.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Expert Opin Pharmacother

Title: Expert opinion on pharmacotherapy

Publisher: Informa UK Limited

ISSN (Electronic): 1744-7666

ISSN (Print): 1465-6566

Publication date (Electronic): Dec 2017

Volume: 18

Issue: 17

Affiliations

[1 ] a National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital/Institute of Mental Health) and the Key Laboratory of Mental Health, Ministry of Health , Beijing , People's Republic of China.

[2 ] b Janssen Research and Development , Shanghai , People's Republic of China.

[3 ] c Janssen Research and Development, LLC , Titusville , NJ , USA.

[4 ] d Janssen Pharmaceutical Companies of Johnson and Johnson , Singapore.

Article

DOI: 10.1080/14656566.2017.1401608

PubMed ID: 29141463

SO-VID: a7a099de-0a94-4c06-940b-ef0eb10a7b0e

History

Keywords: paliperidone palmitate,recently diagnosed schizophrenia,positive and negative syndrome scale (PANSS),Chronic schizophrenia,clinical global impressions – severity (CGI-S),long-acting injectable

Data availability:

Keywords: paliperidone palmitate, recently diagnosed schizophrenia, positive and negative syndrome scale (PANSS), Chronic schizophrenia, clinical global impressions – severity (CGI-S), long-acting injectable

Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety.

Read this article at

Abstract

Related collections

Efficacy of Communicating Science

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 74

Cited by 5